Russian vaccine developer plans to sue Brazilian regulator for defamation
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SATURDAY, MAY 28, 2022
SATURDAY, MAY 28, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Russian vaccine developer plans to sue Brazilian regulator for defamation

Coronavirus chronicle

Reuters
30 April, 2021, 09:15 am
Last modified: 30 April, 2021, 09:15 am

Related News

  • Risk of food insecurity threatens record 36% of Brazilian families
  • Elon Musk to meet with Brazil's Bolsonaro
  • Lula launches presidential bid, says to defend Brazil's democracy
  • CIA chief told Bolsonaro government not to mess with Brazil election, sources say
  • Lula turns to party's old guard for Brazil election battle

Russian vaccine developer plans to sue Brazilian regulator for defamation

"Following the admission of Brazilian regulator Anvisa that it did not test Sputnik V vaccine, Sputnik V is undertaking a legal defamation proceeding in Brazil against Anvisa for knowingly spreading false and inaccurate information," the Sputnik V tweet said

Reuters
30 April, 2021, 09:15 am
Last modified: 30 April, 2021, 09:15 am
Photo: Collected
Photo: Collected

The Russian developer of the Sputnik V coronavirus vaccine said on Thursday that it would sue the Brazilian health regulator Anvisa for defamation, accusing it of knowingly spreading false information.

Anvisa's board on Monday rejected requests to approve Sputnik V for import. Anvisa's medicines and biological products manager Gustavo Mendes said there was evidence an adenovirus used in the vaccine could reproduce, and that this was a serious defect.

Viral vectors are commonly used to transport genetic information for a protein from a pathogen - in this case, the novel coronavirus - that will elicit an immune response in the recipient of the vaccine.

Denis Logunov, who developed Sputnik V at Russia's Gamaleya Center, denied on Tuesday that the two adenoviruses used to produce the vaccine could replicate.

Sputnik V's official Twitter account on Thursday quoted Mendes, who cited the Russians' test results at a public hearing on Monday as the basis to deny an import license.

"Following the admission of Brazilian regulator Anvisa that it did not test Sputnik V vaccine, Sputnik V is undertaking a legal defamation proceeding in Brazil against Anvisa for knowingly spreading false and inaccurate information," the Sputnik V tweet said.

"Anvisa made incorrect and misleading statements without having tested the actual Sputnik V vaccine."

Anvisa did not immediately respond to a request for comment. The agency's standard protocols for approving COVID-19 vaccines involve analysis of the developers' own testing and clinical trials.

World+Biz

Brazil / Sputnik V

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Plucking the poultry: New tax regime for the sector on cards
    Plucking the poultry: New tax regime for the sector on cards
  • Dr Zahid Hussain. Illustration: TBS
    The economics of remittance subsidy
  • The government needs to continue subsidising both agriculture and non-agriculture sectors to keep inflation under control Photo: Mumit M/TBS
    Commodity rally continues

MOST VIEWED

  • People in protective suits cross a street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    Shanghai heading out of lockdown but China still lost in economic gloom
  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Tightening Covid net, Beijing deals out punishments, stark warnings
  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing ramps up Covid quarantine, Shanghai residents decry uneven rules
  • A vial labelled with the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine is seen in this illustration picture taken March 19, 2021. Photo :Reuters
    Pfizer says 3 Covid shots protect children under 5
  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing urges millions to keep working from home amid Covid outbreak menace
  • Picture: PTI
    Saudi Arabia bans travel to India, 15 other countries over Covid outbreaks

Related News

  • Risk of food insecurity threatens record 36% of Brazilian families
  • Elon Musk to meet with Brazil's Bolsonaro
  • Lula launches presidential bid, says to defend Brazil's democracy
  • CIA chief told Bolsonaro government not to mess with Brazil election, sources say
  • Lula turns to party's old guard for Brazil election battle

Features

The taboo of dining out alone

The taboo of dining out alone

12h | Food
The perfect time for newborn photography is between the first five and 14 days when a baby’s bones are the most malleable for posing. Photo: Courtesy

Is there a market for newborn photography in the country? Studio Picturerific says yes

12h | Panorama
Pakistan finds itself in political turmoil again as Imran Khan pushes for immediate general elections. Photo: Reuters

Supreme Court of Pakistan: Now a candle in the dark

14h | Analysis
Indulge in Momium’s guilt-free dips and spreads

Indulge in Momium’s guilt-free dips and spreads

14h | Food

More Videos from TBS

Fear of food crisis sets across the globe

Fear of food crisis sets across the globe

8h | Videos
Is Mushfiq refraining from self-destructive shots?

Is Mushfiq refraining from self-destructive shots?

8h | Videos
Kanak is ahead of everyone in Guinness Book

Kanak is ahead of everyone in Guinness Book

13h | Videos
What should your CV cover letter look like?

What should your CV cover letter look like?

15h | Videos

Most Read

1
Bangladesh at risk of losing ownership of Banglar Samriddhi
Bangladesh

Bangladesh at risk of losing ownership of Banglar Samriddhi

2
Corporates go cashless…tax cut on cards
NBR

Corporates go cashless…tax cut on cards

3
Photo: Courtesy
Panorama

Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh

4
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

5
British International Investment (BII) CEO Nick O’Donohoe. Illustration: TBS
Economy

BII to invest $450m in Bangladesh in 5 years

6
Representational image. Picture: Pixabay
Economy

Govt raises regulatory duty to discourage imports of 130 products

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab